EUVIMEDEUVIMED entdecken
Open Access

In vitro selection and analysis of SARS-CoV-2 nirmatrelvir resistance mutations contributing to clinical virus resistance surveillance

Yuao Zhu iD, Irina Yurgelonis iD, Stephen Noell iD, Qingyi Yang, Shunjie Guan, Zhenghui Li, Li Hao iD, Hussin Rothan, Devendra K Rai, Patricia McMonagle iD, Mary Lynn Baniecki iD, Samantha E Greasley iD und 13 weitere

Science Advances · 2024

DOI: 10.1126/sciadv.adl4013 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Advances, 2024. Verfasst von Yuao Zhu und 24 weiteren Autor:innen. Beteiligte Einrichtung: Pfizer Worldwide Research, Development & Medical, Pearl River, NY 10965, USA. Hauptthemen laut MEDLINE: SARS-CoV-2, Drug Resistance, Viral, Antiviral Agents, Mutation. Die Arbeit wurde bisher 61-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

To facilitate the detection and management of potential clinical antiviral resistance, in vitro selection of drug-resistant severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) against the virus M pro inhibitor nirmatrelvir (Paxlovid active component) was conducted. Six M pro mutation patterns containing T304I alone or in combination with T21I, L50F, T135I, S144A, or A173V emerged, with A173V+T304I and T21I+S144A+T304I mutations showing >20-fold resistance each. Biochemical analyses indicated inhibition constant shifts aligned to antiviral results, with S144A and A173V each markedly reducing nirmatrelvir inhibition and M pro activity. SARS-CoV-2 surveillance revealed that in vitro resistance–associated mutations from our studies and those reported in the literature were rarely detected in the Global Initiative on Sharing All Influenza Data database. In the Paxlovid Evaluation of Protease Inhibition for COVID-19 in High-Risk Patients trial, E166V was the only emergent resistance mutation, observed in three Paxlovid-treated patients, none of whom experienced COVID-19–related hospitalization or death.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SARS-CoV-2Drug Resistance, ViralAntiviral AgentsMutationCOVID-19 Drug TreatmentHumansCOVID-19Coronavirus 3C ProteasesLactamsLeucineNitrilesProline

Substanzen

Antiviral AgentsnirmatrelvirCoronavirus 3C ProteasesLactamsLeucineNitrilesProline

Autor:innen und Institutionen

  • Pfizer Worldwide Research, Development & Medical, Pearl River, NY 10965, USA.
  • Pfizer Worldwide Research, Development & Medical, Groton, CT 06340, USA.
  • Pfizer Worldwide Research, Development & Medical, Cambridge MA 02139, USA.
  • Pfizer Worldwide Research, Development & Medical, La Jolla, CA 92121, USA.

ORCID-Profile: Yuao Zhu, Irina Yurgelonis, Stephen Noell, Li Hao, Patricia McMonagle, Mary Lynn Baniecki, Samantha E Greasley, Jennifer A Nicki, RoseAnn Ferre, Laura J Byrnes, Timothy K Craig, Claire M Steppan, Paul Liberator, Holly D Soares, Charlotte M N Allerton, Rhonda D Cardin

Zitieren

APA

Zhu, Y., Yurgelonis, I., Noell, S., Yang, Q., Guan, S., Li, Z., Hao, L., Rothan, H., Rai, D. K., McMonagle, P., Baniecki, M. L., Greasley, S. E., Plotnikova, O., Lee, J., Nicki, J. A., Ferre, R., Byrnes, L. J., Liu, W., Craig, T. K., …, & Cardin, R. D. (2024). In vitro selection and analysis of SARS-CoV-2 nirmatrelvir resistance mutations contributing to clinical virus resistance surveillance. Science Advances. https://doi.org/10.1126/sciadv.adl4013

Vancouver

Zhu Y, Yurgelonis I, Noell S, Yang Q, Guan S, Li Z, et al. In vitro selection and analysis of SARS-CoV-2 nirmatrelvir resistance mutations contributing to clinical virus resistance surveillance. Science Advances. 2024. doi:10.1126/sciadv.adl4013

BibTeX
@article{Zhu2024,
  author = {Zhu, Yuao and Yurgelonis, Irina and Noell, Stephen and Yang, Qingyi and Guan, Shunjie and Li, Zhenghui and Hao, Li and Rothan, Hussin and Rai, Devendra K and McMonagle, Patricia and Baniecki, Mary Lynn and Greasley, Samantha E and Plotnikova, Olga and Lee, Jonathan and Nicki, Jennifer A and Ferre, RoseAnn and Byrnes, Laura J and Liu, Wei and Craig, Timothy K and Steppan, Claire M and Liberator, Paul and Soares, Holly D and Allerton, Charlotte M N and Anderson, Annaliesa S and Cardin, Rhonda D},
  title = {In vitro selection and analysis of SARS-CoV-2 nirmatrelvir resistance mutations contributing to clinical virus resistance surveillance},
  journal = {Science Advances},
  year = {2024},
  doi = {10.1126/sciadv.adl4013}
}
Kostenlos starten →